PharmaShots | Incisive News in 3 Shots

Subscribe Now

Palisade Bio

The Canadian Intellectual Property Office (CIPO) Issues Notice of Allowance for Patent Covering Palisade Bio’s PALI-2108 for Treating Ulcerative Colitis

The Canadian Intellectual Property Office (CIPO) Issues Notice of Allowance for Patent Covering Palisade Bio’s PALI-2108 for Treat...

June 12, 2024

Palisade Bio Reports P-II Study (PROFILE) Results of LB1148 for Post-Surgical Abdominal Adhesions

August 10, 2023

Palisade Bio Development Partner Newsoara Report the First Patient Enrolment of LB1148 in P-III Trial to protect Gastrointestinal Integrity in Surgery Patients

Palisade Bio Development Partner Newsoara Report the First Patient Enrolment of LB1148 in P-III Trial to protect Gastrointestinal...

April 6, 2023

Palisade Bio Reports First Patient Enrollment in P-III Study of LB1148 for Postoperative Return of Bowel Function

Palisade Bio Reports First Patient Enrollment in P-III Study of LB1148 for Postoperative Return of Bowel Function

July 28, 2022

Palisade Bio and Newsoara’s LB1148 Receive NMPA’s Clearance to Initiate P-III Trial to Improve Bowel Function After Abdominal Surgery

Palisade Bio and Newsoara’s LB1148 Receive NMPA’s Clearance to Initiate P-III Trial to Improve Bowel Function After Abdominal Surg...

May 6, 2022

Palisade Bio Receives the US FDA’s Study May Proceed Letter for P-III Clinical Trial of LB1148 to Improved Bowel Function After Abdominal Surgery

Palisade Bio Receives the US FDA’s Study May Proceed Letter for P-III Clinical Trial of LB1148 to Improved Bowel Function After Ab...

March 23, 2022

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us